Andelyn Biosciences, Inc., a leading contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, has announced a new partnership with Amplo Biotechnology to support the development and manufacturing of gene therapies targeting neuromuscular junction (NMJ) disorders.
The collaboration will focus on producing clinical-grade adeno-associated virus (AAV) material using Andelyn’s proprietary Curator platform—a scalable, data-driven suspension AAV manufacturing system designed for rapid adaptation and optimization from development through commercial production.
NMJ disorders are a group of rare and often debilitating conditions characterized by muscle weakness, which in severe cases can lead to respiratory failure, loss of mobility, or reliance on tube feeding. These genetic diseases often present in childhood but may also develop later in life. Many forms can be life-threatening without effective treatment.
Through this partnership, Amplo Biotechnology will advance its AAV-based gene therapy programs toward clinical trials, prioritizing safety, efficacy, and scalability.
“As a leading clinical and commercial CDMO, we are honored to support Amplo Biotechnology’s efforts to bring hope to patients affected by debilitating NMJ diseases,” said Matt Niloff, Chief Commercial Officer at Andelyn Biosciences. “Our Curator platform and end-to-end capabilities are designed to help partners achieve key development and clinical milestones.”
Amplo Biotechnology noted that the collaboration strengthens its ability to produce high-quality AAV materials and aligns with its mission to develop transformative therapies for families living with genetic NMJ conditions.
Operating out of its advanced facilities in Columbus, Ohio, Andelyn Biosciences continues to play a critical role in accelerating gene therapy innovation by offering full-spectrum development and manufacturing support. This partnership with Amplo Biotechnology highlights Andelyn’s growing impact on the future of genetic medicine and its commitment to improving patient outcomes through science and collaboration.